Skip to main content
Andrew Goodman, MD, Neurology, Rochester, NY, Strong Memorial Hospital of the University of Rochester

AndrewDGoodmanMDFAAN, FANA

Neurology Rochester, NY

Neuroimmunology/Multiple Sclerosis

Professor of Neurology; Chief, Neuroimmunology Division; Director, Multiple Sclerosis Center

Dr. Goodman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Goodman's full profile

Already have an account?

  • Office

    601 Elmwood Ave
    URMC Box 605; Room 6-8521
    Rochester, NY 14642
    Phone+1 585-275-7854
    Fax+1 585-275-9953
  • Is this information wrong?

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterNeuroimmunology, 1983 - 1988
  • Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital
    Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Neurology, 1979 - 1983
  • Rutgers New Jersey Medical School
    Rutgers New Jersey Medical SchoolClass of 1979

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1981 - 2025
  • MD State Medical License
    MD State Medical License 1985 - 1988
  • American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • NeuroGenesis Receives FDA Clearance for Phase IIb Study
    NeuroGenesis Receives FDA Clearance for Phase IIb StudyApril 24th, 2023
  • #AAN2019 — Ibudilast Slows Brain Atrophy in PPMS but Not SPMS Patients, Phase 2b Trial Shows
    #AAN2019 — Ibudilast Slows Brain Atrophy in PPMS but Not SPMS Patients, Phase 2b Trial ShowsApril 4th, 2019
  • MediciNova Announces Upcoming Presentations Regarding the SPRINT-MS Phase 2b Trial of MN-166 (Ibudilast) in Progressive Multiple Sclerosis at the 71st American Academy of Neurology Annual Meeting in Philadelphia, Pennsylvania
    MediciNova Announces Upcoming Presentations Regarding the SPRINT-MS Phase 2b Trial of MN-166 (Ibudilast) in Progressive Multiple Sclerosis at the 71st American Academy of Neurology Annual Meeting in Philadelphia, PennsylvaniaMarch 24th, 2019
  • Join now to see all

Grant Support

  • Public Prevention Health Fund: Community Transformation GrantsNational Center For Chronic Disease Prev And Health Promo2011
  • Antegren/ Intramuscular Interferon Beta 1A In MSNational Center For Research Resources2000–2002
  • Study Of IV Antegren In Patients With MS During Acute ExaserbationNational Center For Research Resources1998–2002
  • Study To Assess Pharmacokinetics Of ESC Dose Of Fampridinein In MS PatientsNational Center For Research Resources1998–2001
  • Longterm OPEN Label Study To Evaluate Safety Of Copaxone In Multiple SclerosisNational Center For Research Resources1996–1997
  • Quantitative Assessment Of Fampridine For Motor Deficits In MSNational Center For Research Resources1996
  • Phase II Titration Study Of Fampridine Administered BID In Multiple SclerosisNational Center For Research Resources1996
  • Lymphocyte B-Adrenergic Receptors In Multiple SclerosisNational Center For Research Resources1992–1993

Hospital Affiliations